Welcome to Grifols. We are an emerging CDMO partner with a focus on producing challenging proteins made in microbial hosts.

Grifols has more than 25 years of experience in recombinant protein technology and we partner with companies interested in developing complex proteins into therapeutics, vaccines, or diagnostics.

We have a cGMP biological manufacturing facility in the San Francisco Bay Area for long-term, high-quality, commercial manufacturing of recombinant biologic drug substance and specializes in recombinant E. coli, yeast and cell culture production. 

We are also a provider of Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Hepatitis B Virus (HBV) antigens for immunoassay diagnostics.  Whether you want antigens from our current menu or custom proteins, our specialists will partner with you to leverage our core development and manufacturing capabilities to provide high-quality, recombinant proteins for your program.


The Benefits of partnering with Grifols
Grifols is ready to partner with you to support development of complex proteins into new therapeutics, diagnostics and vaccines.

Grifols has development and cGMP production capacity for recombinant proteins in yeast.

cGMP production of recombinant proteins made in E. coli is performed in Grifols’ new state-of-the-art facility.

Grifols excels in expressing complex, challenging proteins that don’t fit into a predefined program.  Our scientists are creative and innovative applying new techniques to solve problems of yield, protein folding, purity, and more.  The best projects are those that have never been done before and have the potential to change the view of medicine or manufacturing.


Grifols has analytical method development and testing to support all stages of product development and manufacturing.

Grifols supplies recombinant Human Immunodeficiency Virus (HIV) antigens including HIV-1, HIV-2 and HIV-1 Type O from the envelope and gag regions.  These antigens are currently used in immunoassays that test blood donations worldwide as well as clinical testing of patients.

Grifols supplies recombinant antigens from the Core, NS3, NS4 and NS5 regions of the Hepatitis C Virus (HCV) genome.  These antigens are currently used in immunoassays that test >60% of the blood donations worldwide as well as clinical testing of patients.

Grifols supplies recombinant Hepatitis B Virus (HBV) core antigen for immunoassay diagnostics.  This antigen is used in immunoassays that test  blood donations worldwide as well as clinical testing of patients.

Our HBV antigen is a licensed biologic with the FDA.


Grifols Recombinant Protein CDMO Services

4560 Horton Street

Emeryville, CA 94608


Phone: 510-923-6540

Contact: Paul Magreta


  • Innovation And Flexibility During The COVID-19 Pandemic

    The biopharmaceutical industry has been challenged to discover and develop new diagnostic tests, treatments, and vaccines to help resolve the pandemic. Learn how one CDMO embraces this challenge as they collaborate with customers to develop and manufacture new molecules.

  • Improve Biopharma Fermentation With Innovation, Collaboration

    Organizations developing products requiring fermentation often create custom processes from scratch, leaving room for inefficiencies, lost value, and, in the case of significant error, costly time delays.

  • Optimizing CDMO Technical Transfer

    Learn how a CDMO helps biopharma organizations predict and mediate technical transfer risks before they become costly, time-consuming problems.

  • Grifols Recombinant Protein CDMO

    Grifols Recombinant Protein CDMO, in Emeryville, California, produces recombinant proteins for therapeutics and diagnostics. With services ranging from concept to process development to GMP manufacturing, we look forward to partnering with you to bring your vision to life, together.

  • Virtual Panel: Leveraging A Biomanufacturing Legacy To Support New Business

    Grifols Recombinant Protein CDMO has three decades of experience manufacturing recombinant proteins. Recently, the business expanded to apply its experience to producing therapeutic proteins for biopharmaceutical organizations at its new GMP consolidated manufacturing facility (CMF) on its Emeryville, CA, campus. Seven diverse experts discuss how the group’s legacy and recent investments support its future in providing recombinant protein CDMO services.

  • Growing With A Flexible, Collaborative CDMO

    Choosing a CDMO that is agile, innovative, and exhibits a willingness to invest in new equipment, infrastructure and services will allow the innovator company and the CDMO to grow together.

  • Explore Alternative Analytical Methods To Solve Process Challenges

    Successful and rapid analytical method development plays a key role in ensuring the development of robust processes to produce high-quality products. 

  • Quality Assurance And Your CDMO

    The result of regulatory compliance with quality standards is binary, but the processes employed to get there don't need to be rigid, inefficient, and expensive. Learn how innovation drives efficiencies.

  • Grifols New Manufacturing Facility Provides Contract Development And Manufacturing Solutions For Recombinant Proteins

    Grifols' Consolidated Manufacturing Facility (CMF) is a flexible, multiproduct facility with available manufacturing capacity that created an opportunity to leverage their existing technical expertise and commitment to quality to provide contract services to biopharma companies as a recombinant protein CDMO and support the development of innovative therapies. We recently spoke with Paul Magreta at Grifols about their new $80 million manufacturing facility in Emeryville, California, and the CDMO Services they offer. 

  • Grifols Achieves Key Milestone With FDA Approval Of The New Consolidated Manufacturing Facility (CMF) For Production Of Recombinant Proteins

    Emeryville, CA - Grifols (MCE: GRF, MCE: GRF.P andNASDAQ: GRFS), a global healthcare company with a history of more than 75 years of improving people's health and well-being and a leader in the development of innovative diagnostic solutions, recently received approval from the U.S. Food & Drug Administration to relocate existing immunodiagnostic manufacturing operations to a new Consolidated Manufacturing Facility (CMF) in Emeryville, California